SALEM (Oregon Right to Life) — Emergency personnel earlier this year reportedly transported an Oregon woman from the Salem Planned Parenthood abortion facility to the hospital following a “medication related procedure.”
Operation Rescue – a pro-life organization that tracks and reports on medical emergencies that occur at abortion facilities – reported on the incident in an online post June 9.
According to the information obtained by Operation Rescue, emergency responders took the the 33-year-old woman to Salem Memorial Hospital on April 13 following a “medication related procedure” at the Planned Parenthood abortion facility on Wolverine Street in Salem.
Operation Rescue submitted public records requests and obtained the unredacted CAD (Computer-Aided Dispatch) report that provides details about the incident. In the CAD report, the woman is described as having experienced “heavy vaginal bleeding, passing large clots,” and “feeling faint.” She was transported to Salem Memorial Hospital. Her current condition is not publicly known.
While it’s unclear precisely what triggered the incident, Operation Rescue said the available data gives strong reason to believe it was an adverse event associated with a chemical abortion.
Operation Rescue President Troy Newman reacted to the report, highlighting the fact that the incident underscores the risks associated with abortion drugs which now account for over 60% of abortions nationwide.
“While pro-abortion advocates frequently characterize ‘abortion pills’ as safe and routine, emergencies such as this woman’s uncontrollable bleeding demonstrate again that significant complications—even requiring hospitalization—can and do occur,” Newman said.
RELATED: FDA Confirms It’s Moving Forward with New Phase of Mifepristone Safety Review
Abortion drugs work by starving the unborn human being of the growth hormone progesterone, then inducing contractions to expel the body after the embryo or fetus has died. But adverse events associated with mifepristone, as acknowledged by the FDA, include hemorrhaging, incomplete abortion, and even fatal infections. A 2023 analysis found the adverse reaction rate to be approximately one in 10, sparking a safety review by the FDA that is currently underway.
The removal of FDA regulations requiring the drugs to be dispensed in-person, and their subsequent distribution via mail, places women at further risk of adverse events, as well as coercion and forced abortion when individuals other than pregnant women are able to more easily obtain the dangerous drugs.
